Pharmacogenetics of antidepressants and mood stabilizers

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 715-744

  Serretti, Alessandro ^a   Gibiino, Sara ^a   Olgiati, Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861168561     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00043-7     Document Type: Chapter

References (325)

1. Abou-Saleh M.T. Who responds to prophylactic lithium therapy?. Br J Psychiatry 1993, 20-26.
2. Abou-Saleh M.T., Coppen A.J. Predictors of long-term outcome of mood disorders on prophylactic lithium. Lithium 1990, 1:27-35.
3. Acquas E., Fibiger H.C. Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex. Psychopharmacology 1996, 125:162-167.
4. Alda M. Pharmacogenetics of lithium response in bipolar disorder. J Psychiatry Neurosci 1999, 24:154-158.
5. Alda M., Grof P., Grof E., et al. Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatr Scand 1994, 90:304-310.
6. Anisman H., Ravindran A.V., Griffiths J., et al. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999, 4:182-188.
7. Anisman H., Kokkinidis L., Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002, 16:544-556.
8. Ansari-Lari M., Muzny D., Lu J., et al. A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res 1996, 6:314-326.
9. Arias B., Catalan R., Gasto C., et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003, 23:563-567.
10. Arias B., Catalan R., Gasto C., et al. Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 2005, 19:166-172.
11. Arias B., Serrett A., Lorenzi C., et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006, 90:251-256.
12. Arinami T., Li L., Mitsushio H., et al. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry 1996, 40:1122-1127.
13. Arranz Estevez F.J. The modulatory role of neurokinins in affective behaviors. Actas Esp Psiquiatr 2005, 33:55-65.
14. Baghai T.C., Schule C., Zwanzger P., et al. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001, 6:258-259.
15. Baghai T., Schule C., Zwanzger P., et al. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett 2002, 328:299-303.
16. Baghai T., Schule C., Zwanzger P., et al. Influence of a functional polymorphism within the angiotensin I-converting enzyme gene on partial sleep deprivation in patients with major depression. Neurosci Lett 2003, 339:223-226.
17. Baghai T.C., Schule C., Zill P., et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett 2004, 363:38-42.
18. Bailey D., Bondar A., Furness L. Pharmacogenomics-it's not just pharmacogenetics. Curr Opin Biotechnol 1998, 9:596-601.
19. Barnes J.C., Costall B., Domeney A.M., et al. Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens. Psychopharmacology 1986, 89:311-316.
20. Bartlett C.W., Gharani N., Millonig J.H., et al. Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int J Dev Neurosci 2005, 23:221-234.
21. Baune B.T., Hohoff C., Berger K., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
22. Baune B.T., Hohoff C., Roehrs T., et al. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?. Neurosci Lett 2008, 436:111-115.
23. Bellivier F., Leroux M., Henry C., et al. Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci Lett 2002, 334:17-20.
24. Bellivier F., Chaste P., Malafosse A. Association between the TPH gene A218C polymorphism and suicidal behavior: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2004, 124:87-91.
25. Benedetti F., Serretti A., Colombo C., et al. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet 2003, 123B:23-26.
26. Benedetti F., Bernasconi A., Lorenzi C., et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004, 355:37-40.
27. Benedetti F., Serretti A., Colombo C., et al. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004, 368:123-126.
28. Benedetti F., Serretti A., Pontiggia A., et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50T/C SNP. Neurosci Lett 2005, 376:51-55.
29. Benedetti F., Colombo C., Pirovano A., et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009, 203:155-160.
30. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59:411-419.
31. Bertilsson L., Dahl M., Dalen P., et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002, 53:111-122.
32. Binder E., Salyakina D., Lichtner P., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319-1325.
33. Bishop J.R., Moline J., Ellingrod V.L., et al. Serotonin 2A-1438G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006, 31:2281-2288.
34. Bobb A.J., Castellanos F.X., Addington A.M., et al. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 2005, 132:109-125.
35. Boess F., Monsma F.J., Carolo C., et al. Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology 1997, 36:713-720.
36. Bondy M. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 2002, 4:21-29.
37. Bondy B., Baghai T., Zill P., et al. Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1094-1099.
38. Booij L., Van der Does A., Riedel W. Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry 2003, 8:951-973.
39. Born G.V.R., Grignani G., Martin K. Long-term effect of lithium on the uptake of 5-hydroxytryptamine by human platelets. Br J Clin Pharmacol 1980, 9:321-325.
40. Bowden C. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000, 61:35-40.
41. Bozina N., Peles A.M., Sagud M., et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 2008, 9:190-197.
42. Brosen K., Naranjo C. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001, 11:275-283.
43. Brosen K., Hansen J., Nielsen K. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993, 44:344-355.
44. Brouwer J.P., Appelhof B.C., van Rossum E.F., et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006, 31:1154-1163.
45. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999, 21:33-37.
46. Campbell D., Sundaramurthy D., Markham A., et al. Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. Genet Test 1997, 1:297-299.
47. Capozzo M.A., Schillani G., Aguglia E., et al. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases. Tumori 2009, 95:479-483.
48. Carli M., Afkhami-Dastjerdian S., Reader T.A. Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochem Res 1997, 22:427-435.
49. Carli M., Morissette M., Hebert C., et al. Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochem Pharmacol 1997, 54:391-397.
50. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
51. Cassidy F., Murry E., Carroll B.J. Tryptophan depletion in recently manic patients treated with lithium. Biol Psychiatry 1998, 43:230-232.
52. Castro M.E., Diaz A., del Olmo E., et al. Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain. Neuropharmacology 2003, 44:93-101.
53. Cavazzoni P., Alda M., Turecki G., et al. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996, 64:91-96.
54. Chen B., Wang J., Sun X., et al. Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biol Psychiatry 2003, 53:530-537.
55. Choi M., Kang R., Ham B., et al. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005, 52:155-162.
56. Cichon S., Buervenich S., Kirov G., et al. Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin. Nat Genet 2004, 36:783-784.
57. Coppen A.J., Swade C., Wood K. Lithium restores abnormal platelet 5-HT transport in patients with affective disoredrs. Br J Psychiatry 1980, 136:235-238.
58. Courtet P., Baud P., Abbar M., et al. Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene. Mol Psychiatry 2001, 6:338-341.
59. Craig S.P., Boularand S., Darmon M.C., et al. Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenet Cell Genet 1991, 56:157-159.
60. Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998, 49:196-201.
61. Crissman A.M., Makhay M.M., O'Donnell J.M. Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl) 2001, 154:70-75.
62. Crowley J.J., Lipsky R.H., Lucki I., et al. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr Genet 2008, 18:248-251.
63. Cusin C., Serretti A., Lattuada E., et al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J Psychiatr Res 2001, 35:217-223.
64. Cusin C., Serretti A., Zanardi R., et al. Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol 2002, 5:27-35.
65. Czeh B., Pudovkina O., van der Hart M., et al. Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression. Psychopharmacology (Berl) 2005, 180:548-557.
66. Dalen P., Dahl M., Ruiz M., et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998, 63:444-452.
67. Dantzer R., Bluthe R., Gheusi G., et al. Molecular basis of sickness behavior. Ann N Y Acad Sci 1998, 856:132-138.
68. Del Zompo M., Ardau R., Palmas M.A., et al. Lithium response: association study with two candidate genes. Mol Psychiatry 1999, 4:s66-s67.
69. Dimitrova A., Milanova V., Krastev S., et al. Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Pharmacogenomics J 2005, 5:35-41.
70. Dmitrzak-Weglarz M., Rybakowski J., Suwalska A., et al. Association studies of 5-HT(2A) and 5-HT(2C) serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol Rep 2005, 57:761-765.
71. Dogan O., Yuksel N., Ergun M.A., et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 2008, 12:225-231.
72. Domschke K., Hohoff C., Mortensen L.S., et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:224-228.
73. Drigues N., Poltyrev T., Bejar C., et al. cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J Neural Transm 2003, 110:1413-1436.
74. Dunn A., Swiergiel A., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
75. Durham L.K., Webb S.M., Milos P.M., et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004, 174:525-529.
76. Einat H., Manji H.K., Belmaker R.H. New approaches to modeling bipolar disorder. Psychopharmacol Bull 2003, 37:47-63.
77. Esposito K., Goodnick P. Predictors of response in depression. Psychiatr Clin North Am 2003, 26:353-365.
78. Fava G.A., Fabbri S., Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1019-1027.
79. Feinn R., Nellissery M., Kranzler H.R. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2005, 133:79-84.
80. Ferreira A.D., Neves F.S., da Rocha F.F., et al. The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord 2009, 112:267-272.
81. Frame S., Cohen P. GSK3 takes centre stage more than 20years after its discovery. Biochem J 2001, 359:1-16.
82. Fyro B., Patterson V., Sedvall G. The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients. Psychopharmacologia 1975, 44:99-103.
83. Garriock H., Allen J., Delgado P., et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005, 10:976-977.
84. Garriock H.A., Kraft J.B., Shyn S.I., et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
85. Gentsch C., Cutler M., Vassout A., et al. Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav Brain Res 2002, 133:363-368.
86. Goldberg J., Garno J., Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Psychiatry Rep 2005, 7:456-461.
87. Goodnick P.J. Predictors of Treatment Response in Mood Disorders. Clinical Practice 1996, American Psychiatric Press, Washington.
88. Goodwin F., Jamison K. Manic-depressive Illness 1990, Oxford University Press, New York.
89. Gottberg E., Montreuil B., Reader T.A. Acute effects of lithium on dopaminergic responses: iontophoretic studies in the rat visual cortex. Synapse 1988, 2:442-449.
90. Gould T.D., Chen G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.
91. Gressier F., Bouaziz E., Verstuyft C., et al. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 2009, 19:195-200.
92. Grof P., Alda M., Grof E., et al. Lithium response and genetics of affective disorders. J Affect Disord 1994, 32:85-95.
93. Guiard B., Lanfumey L., Gardier A. Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr Drug Targets 2006, 7:187-201.
94. Gutierrez B., Pintor L., Gasto C., et al. Variability in the serotonin transporter gene and increased risk for major depression with melancholia. Hum Genet 1998, 103:319-322.
95. Ham B., Lee M., Lee H., et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005, 15:229-301.
96. Ham B.J., Lee B.C., Paik J.W., et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:104-107.
97. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004, 45:104-114.
98. Healy D., Waterhouse J. The circadian system and the therapeutics of the affective disorders. Pharmacol Ther 2005, 65:241-263.
99. Heils A., Teufel A., Petri S., et al. Allelic variation of human serotonin trasporter gene expression. J Neurochem 1996, 66:2621-2624.
100. Hemrick-Luecke S.K., Snoddy H.D., Fuller R.W. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994, 55:479-483.
101. Holmes A., Murphy D.L., Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry 2003, 54:953-959.
102. Holmes A., Yang R.J., Lesch K.P., et al. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 2003, 28:2077-2088.
103. Hong C.J., Wang Y.C., Tsai S.J. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 2002, 109:1209-1214.
104. Hong C., Chen T., Yu Y., et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006, 6:27-33.
105. Hongisto V., Smeds N., Brecht S., et al. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 2003, 23:6027-6036.
106. Horstmann S., Lucae S., Menke A., et al. Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients. Eur Neuropsychopharmacol 2008, 18:S214-S215.
107. Hou S., Yen F., Cheng C., et al. X-box binding protein 1 (XBP1) C-116G polymorphisms in bipolar disorders and age of onset. Neurosci Lett 2004, 367:232-234.
108. Hu X.-Z., Rush A.J., Charney D., et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007, 64:783-792.
109. Huezo-Diaz P., Uher R., Smith R., et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009, 195:30-38.
110. Illi A., Setala-Soikkeli E., Viikki M., et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
111. Ising M., Lucae S., Binder E.B., et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009, 66:966-975.
112. Ito K., Yoshida K., Sato K., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002, 111:235-239.
113. Iwakoshi N., Lee A., Glimcher L. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev 2003, 194:29-38.
114. Jonsson E.G., Goldman D., Spurlock G., et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997, 247:297-302.
115. Jope R.S., Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry 2002, 7:35-45.
116. Joyce P.R., Mulder R.T., Luty S.E., et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003, 6:339-346.
117. Kakiuchi C., Iwamoto K., Ishiwata M., et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 2003, 35:171-175.
118. Kang R.-H., Wong M.-L., Choi M.-J., et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1317-1321.
119. Kang R.H., Hahn S.W., Choi M.J., et al. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 2007, 56:1-5.
120. Kao C. Functional genomic technologies:creating new paradigms for fundamental and appled biology. Biotechnol Prog 1999, 15:304-311.
121. Kato T., Kunugi H., Nanko S., et al. Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord 2001, 62:151-164.
122. Kato M., Ikenaga Y., Wakeno M., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005, 20:151-156.
123. Kato T., Kuratomi G., Kato N. Genetics of bipolar disorder. Drugs Today 2005, 41:335-344.
124. Kato M., Fukuda T., Wakeno M., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
125. Kato M., Wakeno M., Okugawa G., et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007, 56:167-171.
126. Kato M., Wakeno M., Okugawa G., et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1041-1044.
127. Kato M., Fukuda T., Wakeno M., et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:115-123.
128. Katzenberg D., Young T., Finn L., et al. A CLOCK polymorphism associated with human diurnal preference. Sleep 1998, 21:569-576.
129. Kaufman R., Scheuner D., Schröder M., et al. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 2001, 3:411-421.
130. Kim D.K., Lim S.W., Lee S., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000, 11:215-219.
131. Kim H., Lim S.-W., Kim S., et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006, 296:1609-1618.
132. King D.P., Vitaterna M.H., Chang A.M., et al. The mouse Clock mutation behaves as a antimorph and maps within the W19H deletion, distal of Kit. Genetics 1997, 146:1049-1060.
133. Kirchheiner J., Brosen K., Dahl M.L., et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001, 104:173-192.
134. Kirchheiner J., Lorch R., Lebedeva E., et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9:841-846.
135. Kirigiti P., Yang Y.F., Li X., et al. Rat beta 1-adrenergic receptor regulatory region containing consensus AP-2 elements recognizes novel transactivator proteins. Mol Cell Biol Res Commun 2000, 3:181-192.
136. Kishi T., Kitajima T., Ikeda M., et al. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Med 2009, 11:53-57.
137. Klemfuss H. Rhythms and the pharmacology of lithium. Pharmacology 1992, 56:53-78.
138. Kohen R., Metcalf M.A., Khan N., et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996, 66:47-56.
139. Kraft J., Slager S., McGrath P., et al. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005, 58:378-381.
140. Kramer M., Winokur A., Kelsey J., et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29:385-392.
141. Kremer I., Bachner-Melman R., Reshef A., et al. Association of the serotonin transporter gene with smoking behavior. Am J Psychiatry 2005, 162:924-930.
142. Kronenberg S., Apter A., Brent D., et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 2007, 17:741-750.
143. Lachman H.M., Morrow B., Shprintzen R., et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996, 67:468-472.
144. Lachman H.M., Kelsoe J.R., Remick R.A., et al. Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am J Med Genet 1997, 74:121-128.
145. Landgrebe J., Welzl G., Metz T., et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res 2002, 36:119-129.
146. Lee H.J., Cha J.H., Ham B.J., et al. Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 2004, 4:29-33.
147. Lee M.S., Lee H.Y., Lee H.J., et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 2004, 14:111-115.
148. Lee S., Lee K., Lee H., et al. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin Neurosci 2005, 59:140-145.
149. Lekman M., Laje G., Charney D., et al. The FKBP5-gene in depression and treatment response-an association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohort. Biol Psychiatry 2008, 63:1103-1110.
150. Lemonde S., Turecki G., Bakish D., et al. Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J Neurosci 2003, 23:8788-8799.
151. Lemonde S., Du L., Bakish D., et al. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Psychopharmacology (Berl) 2004, 24:24.
152. Lesch K.P., Balling U., Gross J., et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994, 95:157-162.
153. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
154. Leuchter A.F., McCracken J.T., Hunter A.M., et al. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 2009, 29:372-377.
155. Levin G.M., Bowles T.M., Ehret M.J., et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007, 11:155-160.
156. Li X., Bijur G., Jope R. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002, 4:137-144.
157. Licinio J., O'Kirwan F., Irizarry K., et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004, 9:1075-1082.
158. Lin J.H., Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998, 35:361-390.
159. Liu Z., Zhu F., Wang G., et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007, 414:155-158.
160. Lovlie R., Berle J., Stordal E., et al. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 2001, 11:41-43.
161. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Psychopharmacology: The Fourth Generation of Progress 1995, 933-944. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
162. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium 1992, 3:15-21.
163. Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000, 2:93-101.
164. Maj M. The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord 2003, 5:180-188.
165. Maj M., Del Vecchio M., Starace F., et al. Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatr Scand 1984, 69:37-44.
166. Maj M., Pirozzi R., Magliano L., et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998, 155:30-35.
167. Malek Z., Dardente H., Pevet P., et al. Tissue-specific expression of tryptophan hydroxylase mRNAs in the rat midbrain: anatomical evidence and daily profiles. Eur J Neurosci 2005, 22:895-901.
168. Mannisto P., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 2005, 51:593-628.
169. Maron E., Tammiste A., Kallassalu K., et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 2009, 19:451-456.
170. Martinek S., Inonog S., Manoukian A.S., et al. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001, 105:769-779.
171. Masoliver E., Menoyo A., Perez V., et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr Genet 2006, 16:25-29.
172. Mason D.A., Moore J.D., Green S.A., et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274:12670-12674.
173. Massot O., Rousselle J.C., Fillion M.P., et al. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacology 1999, 21:530-541.
174. Masui T., Hashimoto R., Kusumi I., et al. A possible association between the [minus sign]116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006, 9:83-88.
175. Matsushita S., Suzuki K., Murayama M., et al. Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet 2004, 128:114-117.
176. McMahon F.J., Buervenich S., Charney D., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:804-814.
177. Melke J., Landen M., Baghei F., et al. Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. Am J Med Genet 2001, 105:458-463.
178. Meltzer H.Y., Arora R.C., Goodnick P.J. Effects of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. J Affect Disord 1983, 5:215-222.
179. Mendlewicz J., Fieve R.R., Stallone F., et al. Genetic history as a predictor of lithium response in manic-depressive illness. Lancet 1972, 1:599-600.
180. Mendlewicz J., Fieve R.R., Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 1973, 130:1011-1013.
181. Meneses A. Role of 5-HT6 receptors in memory formation. Drug News Perspect 2001, 14:396-400.
182. Mignone F., Gissi C., Liuni S., et al. Untranslated regions of mRNAs. Genome Biol 2002, 3. REVIEWS0004.
183. Min W., Li T., Ma X., et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 2009, 205:409-417.
184. Minov C., Baghai T.C., Schule C., et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001, 303:119-122.
185. Moncrieff J., Kirsch I. Efficacy of antidepressants in adults. BMJ 2005, 331:551-557.
186. Moore G.J., Bebchuk J.M., Wilds I.B., et al. Lithium-induced increase in human brain grey matter. Lancet 2000, 356:1241-1242.
187. Morabito A., Gasperini M., Macciardi F., et al. Possible relationship between outcome in primary affective disorders treated with lithium and family history. Adv Biochem Psychopharmacol 1982, 32:157-163.
188. Mrazek D.A., Rush A.J., Biernacka J.M., et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:341-351.
189. Muller D.J., Schulze T.G., Macciardi F., et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase-A promoter. Eighth World Congress on Psychiatric Genetics 2000, Vol. 96:537. Neuropsychiatric Genetics, Wiley-Liss, Versailles, France,.
190. Muller D.J., Schulze T.G., Macciardi F., et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 2002, 35:157-158.
191. Mundo E., Walker M., Cate T., et al. the rtole of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry 2001, 58:539-544.
192. Murphy G.M., Kremer C., Rodrigues H.E., et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003, 160:1830-1835.
193. Murphy G.M., Hollander S.B., Rodrigues H.E., et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004, 61:1163-1169.
194. Nahorski S.R., Ragan C.I., Challiss R.A. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol Sci 1991, 12:297-303.
195. Nebert D., Dieter M. The evolution of drug metabolism. Pharmacology 2002, 61:124-135.
196. Neer E.J. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995, 80:249-257.
197. Nemeroff C., Vale W. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005, 66:5-13.
198. Ng C.H., Easteal S., Tan S., et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:953-957.
199. Niculescu A.B., Segal D.S., Kuczenski R., et al. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics 2000, 4:83-91.
200. Nielsen D.A., Jenkins G.L., Stefanisko K.M., et al. Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res 1997, 45:145-148.
201. Nierenberg A.A. Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am 2003, 26:345-352.
202. Nobile M., Cataldo M.G., Giorda R., et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry 2004, 56:292-295.
203. O'Connell R.A., Mayo J.A., Flatow L., et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991, 159:123-129.
204. O'Reilly R.L., Bogue L., Singh S.M. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994, 36:467-471.
205. Odagaki Y., Koyama T., Matsubara S., et al. Effects of chronic lithium treatment on serotonin binding sites in rat brain. J Psychiatr Res 1990, 24:271-277.
206. Ogilvie A.D., Battersby S., Bubb V.J., et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996, 347:731-733.
207. Orsini A. Antidepressant responses and segregation analyses in affective families. Anxious Depression: Assessment and Treatment 1987, 1155-1170. Raven Press, New York. G. Racagni, E. Smeraldi (Eds.).
208. Overstreet D., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004, 497:49-53.
209. Ozdemir V., Tyndale R., Reed K. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 1999, 19:472-475.
210. Palotas A., Puskas L., Kitajka K., et al. The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem Res 2004, 29:1563-1570.
211. Papiol S., Arias B., Gasto C., et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007, 104:83-90.
212. Pare C.M., Rees L., Sainsbury M.J. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 1962, 2:1340-1343.
213. Park J.W., Kim J.S., Lee H.K., et al. Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache 2004, 44:1005-1009.
214. Parsey R.V., Olvet D.M., Oquendo M.A., et al. Higher 5-HT(1A) receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006, 31:1745-1749.
215. Perez V., Gilaberte I., Faries D., et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997, 349:1594-1597.
216. Perlis R.H., Mischoulon D., Smoller J.W., et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003, 54:879-883.
217. Perlis R.H., Fijal B., Adams D.H., et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009, 65:785-791.
218. Peters E.J., Slager S.L., McGrath P.J., et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004, 9:879-889.
219. Peters E.J., Slager S.L., Jenkins G.D., et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009, 19:1-10.
220. Pollock B.G., Ferrell R.E., Mulsant B.H., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
221. Popp J., Leucht S., Heres S., et al. Serotonin transporter polymorphisms and side effects in antidepressant therapy - a pilot study. Pharmacogenomics 2006, 7:159-166.
222. Post R.M., Susan R., Weiss B. Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 1992, 25:41-43.
223. Price L.H., Charney D.S., Delgado P.L., et al. Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. Arch Gen Psychiatry 1989, 46:13-19.
224. Quiroz J., Gould T., Manji H. Molecular effects of lithium. Mol Interv 2004, 4:259-272.
225. Quiroz J.A., Singh J., Gould T.D., et al. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry 2004, 9:756-776.
226. Quitkin F., McGrath P., Stewart J., et al. Can the effects of antidepressants be observed in the first two weeks of treatment?. Neuropsychopharmacology 1996, 15:390-394.
227. Ramamoorthy S., Bauman A.L., Moore K.R., et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1993, 90:2542-2546.
228. Rausch J.L., Johnson M.E., Fei Y.-J., et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatry 2002, 51:723-732.
229. Reppert S., Weaver D. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001, 63:647-676.
230. Reul J., Holsboer F. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 2002, 4:31-46.
231. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
232. Roden D., George A.J. The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002, 1:37-44.
233. Rogers D., Hagan J. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 2001, 158:114-119.
234. Rousseva A., Henry C., Van Den Bulke D., et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J 2003, 3:101-104.
235. Rujescu D., Giegling I., Sato T., et al. Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatry 2003, 54:465-473.
236. Rybakowski J., Suwalska A., Skibinska M., et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005, 38:166-170.
237. Sabol S.Z., Hu S., Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998, 103:273-279.
238. Sato K., Yoshida K., Takahashi H., et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46:136-140.
239. Schiepers O., Wichers M., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
240. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
241. Schillani G., Capozzo M.A., Aguglia E., et al. 5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: report of eleven cases. Tumori 2008, 94:563-567.
242. Schinkel A., Wagenaar E., Mol C., et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:2517-2524.
243. Schwarz M., Ackenheil M. The role of substance P in depression: therapeutic implications. Dialogues Clin Neurosci 2002, 4:21-29.
244. Serretti A., Franchini L., Gasperini M., et al. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr Scand 1998, 98:443-450.
245. Serretti A., Lilli R., Lorenzi C., et al. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmacol 1998, 1:125-129.
246. Serretti A., Lilli R., Lorenzi C., et al. Dopamine receptor D2, D4, GABAA alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res 1999, 87:7-19.
247. Serretti A., Lilli R., Lorenzi C., et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 1999, 33:371-377.
248. Serretti A., Lorenzi C., Lilli R., et al. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000, 34:89-98.
249. Serretti A., Lilli R., Mandelli L., et al. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001, 1:71-77.
250. Serretti A., Zanardi R., Cusin C., et al. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res 2001, 104:195-203.
251. Serretti A., Zanardi R., Cusin C., et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001, 11:375-380.
252. Serretti A., Zanardi R., Rossini D., et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001, 6:586-592.
253. Serretti A., Benedetti F., Mandelli L., et al. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet 2003, 121B:39-43.
254. Serretti A., Lorenzi C., Cusin C., et al. SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol 2003, 13:117-122.
255. Serretti A., Artioli P., Lorenzi C., et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004, 7:453-460.
256. Serretti A., Artioli P., Zanardi R., et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl) 2004, 174:504-511.
257. Serretti A., Cusin C., Rossini D., et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet 2004, 129B:36-40.
258. Serretti A., Malitas P., Mandelli L., et al. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J 2004, 4:267-273.
259. Serretti A., Cusin C., Benedetti F., et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 10:10.
260. Serretti A., Calati R., Mandelli L., et al. Serotonin transporter gene variants and behaviour: a comprehensive review. Curr Drug Targets 2006, 7:1659-1669.
261. Seymour P., Schmidt A., Schulz D. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 2003, 9:57-96.
262. Shaltiel G., Shamir A., Shapiro J., et al. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004, 56:868-874.
263. Siffert W., Rosskopf D., Siffert G., et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998, 18:45-48.
264. Silverstone P., McGrath B., Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005, 7:1-10.
265. Skrebuhhova T., Allikmets L., Matto V. Effects of anxiogenic drugs in rat forced swimming test. Methods Find Exp Clin Pharmacol 1999, 21:173-178.
266. Smeraldi E., Petroccione A., Gasperini M., et al. The search for genetic homogeneity in affective disorders. J Affect Disord 1984, 7:99-107.
267. Smeraldi E., Petroccione A., Gasperini M., et al. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J Affect Disord 1984, 6:139-151.
268. Smeraldi E., Zanardi R., Benedetti F., et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511.
269. Smeraldi E, Serretti A, Artioli P, et al. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet Aug 2006, 16:153-158.
270. Smits K.M., Smits L.J., Peeters F.P., et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008, 18:184-190.
271. Stamm T.J., Adli M., Kirchheiner J., et al. Serotonin transporter gene and response to lithium augmentation in depression. Psychiatr Genet 2008, 18:92-97.
272. Steen V.M., Lovlie R., Osher Y., et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998, 8:259-268.
273. Steeves T.D., King D.P., Zhao Y., et al. Molecular cloning and characterization of the human clock gene: mexpression in the suprachiasmatic nuclei. Genomics 1999, 57:198-200.
274. Steiger H., Joober R., Israel M., et al. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord 2005, 37:57-60.
275. Suppes T., Dennehy E., Gibbons E. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000, 61:23-30.
276. Suzuki Y., Sawamura K., Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics 2004, 4:283-286.
277. Suzuki Y., Sawamura K., Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006, 31:825-831.
278. Swann A.C., Koslow S.H., Katz M.M., et al. Lithium carbonate treatment of mania: cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 1987, 44:345-354.
279. Szegedi A., Rujescu D., Tadic A., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005, 5:49-53.
280. Tadic A., Muller M.J., Rujescu D., et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007, 144:325-331.
281. Takahashi H., Yoshida K., Ito K., et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002, 12:477-481.
282. Tanaka M., Kobayashi D., Murakami Y., et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008, 11:261-267.
283. Thiebaut F., Tsuruo T., Hamada H. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84:7735-7738.
284. Tranter R., O'Donovan C., Chandarana P., et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002, 27:241-247.
285. Tsai S.J., Hong C.J., Chen T.J., et al. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1097-1098.
286. Tsai S.J., Gau Y.T., Hong C.J., et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009, 113:183-187.
287. Tsai S.J., Hong C.J., Liou Y.J., et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:637-641.
288. Turecki G., Alda M., Grof P., et al. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Res 1996, 63:17-23.
289. Turecki G., Grof P., Cavazzoni P., et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998, 3:534-538.
290. Tzeng D.S., Chien C.C., Lung F.W., et al. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol 2009, 24:293-300.
291. Tzvetkov M.V., Brockmoller J., Roots I., et al. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 2008, 18:495-506.
292. Uher R., Huezo-Diaz P., Perroud N., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009, 9:225-233.
293. Uhr M. ABCB1 genotyping is crucial for treatment with drugs that are P-glycoprotein substrates. Biol Psychiatry 2005, 57:785.
294. van Kammen D.P., Docherty J.P., Marder S.R., et al. Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia. Psychopharmacology 1985, 87:111-115.
295. van Rossum E.F.C., Binder E.B., Majer M., et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006, 59:681-688.
296. Veefkind A., Haffmans P., Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000, 22:202-208.
297. Walther D.J., Peter J.U., Bashammakh S., et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299:76.
298. Washizuka S., Ikeda A., Kato N., et al. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003, 6:421-424.
299. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003, 348:529-537.
300. Weinshilboum R.M., Otterness D.M., Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999, 39:19-52.
301. Wilkie M.J., Smith D., Reid I.C., et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 2007, 17:207-215.
302. Wilkie M.J., Smith G., Day R.K., et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009, 9:61-70.
303. Wu S., Comings D.E. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet 1999, 9:105-106.
304. Wu W.H., Huo S.J., Cheng C.Y., et al. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001, 44:172-175.
305. Yamada M., Yamada M., Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:999-1009.
306. Yang-Feng T.L., Xue F.Y., Zhong W.W., et al. Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci U S A 1990, 87:1516-1520.
307. Yeo A., Boyd P., Lumsden S., et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004, 53:1452-1458.
308. Yoshida K., Ito K., Sato K., et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:383-386.
309. Yoshida K., Naito S., Takahashi H., et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1279-1283.
310. Yoshida K., Naito S., Takahashi H., et al. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003, 48:10-13.
311. Yoshida K., Takahashi H., Higuchi H., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004, 161:1575-1580.
312. Yoshida K., Higuchi H., Takahashi H., et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008, 23:121-128.
313. Yoshimura R., Umene-Nakano W., Suzuki A., et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 2009, 24:489-494.
314. Yu Y.W., Tsai S.J., Chen T.J., et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002, 7:1115-1119.
315. Yu Y.W., Chen T.J., Hong C.J., et al. Association study of the interleukin-1beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003, 28:1182-1185.
316. Yu Y., Tsai S., Hong C., et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005, 30:1719-1723.
317. Yu Y.W., Tsai S.J., Liou Y.J., et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006, 16:498-503.
318. Zanardi R., Benedetti F., DiBella D., et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000, 20:105-107.
319. Zanardi R., Serretti A., Rossini D., et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001, 50:323-330.
320. Zangen A., Nakash R., Overstreet D.H., et al. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl) 2001, 155:434-439.
321. Zhang X., Gainetdinov R., Beaulieu J.-M., et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005, 45:11-16.
322. Zill P., Baghai T.C., Zwanzger P., et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000, 11:1893-1897.
323. Zill P., Baghai T.C., Engel R., et al. The beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment. Xth World Congress of Psychiatric Genetics 2002, Vol. 114:777. Wiley-Liss, New York. M. Tsuang (Ed.).
324. Zill P., Baghai T.C., Engel R., et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet 2003, 120B:85-89.
325. Zill P., Buttner A., Eisenmenger W., et al. Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. J Psychiatr Res 2005, 41:168-173.